Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Austin

Internal Medicine Oklahoma City, OK Doctor of Osteopathy

NPI 1861753287 CMS profile 1850365

608 Nw 9Th St, Suite 3110 & 4106, Oklahoma City, OK 73102

Open in the dashboard

General payments

$5,265

348 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Austin of Oklahoma City, OK is reported in the CMS Open Payments database as having received $5,265 across 348 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,272 78
2024 General $1,474 97
2023 General $1,485 98
2022 General $401 28
2021 General $299 20
2020 General $68 5
2019 General $266 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Austin
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Matthew Austin were reported at $1,272. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Matthew Austin Internal Medicine median Middle half National median
2019 $266 $159 $48–$570 $163
2020 $68 $119 $33–$402 $114
2021 $299 $135 $37–$521 $132
2022 $401 $141 $42–$496 $149
2023 $1,485 $149 $45–$519 $160
2024 $1,474 $154 $47–$537 $164
2025 $1,272 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $719 51 payments
  2. GlaxoSmithKline, LLC. $694 60 payments
  3. AbbVie, Inc. $576 39 payments
  4. Lilly USA, LLC $437 29 payments
  5. Abbott Laboratories $436 31 payments
  6. Novo Nordisk Inc $401 29 payments
  7. AstraZeneca Pharmaceuticals LP $397 19 payments
  8. Astellas Pharma US Inc $218 11 payments
  9. Amgen Inc. $153 9 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $152 8 payments
  11. Other $1,082 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,265 348 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $445 36 payments
  2. FreeStyle Libre 3 $404 29 payments
  3. COMIRNATY $385 26 payments
  4. AIRSUPRA $384 18 payments
  5. PREVNAR 20 $361 24 payments
  6. ABRYSVO $291 19 payments
  7. NURTEC ODT $262 20 payments
  8. QULIPTA $259 18 payments
  9. MOUNJARO $232 16 payments
  10. ZAVZPRET $226 17 payments
  11. Other $4,167 269 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 158 drugs

Part D claims

9,810

Median for Internal Medicine: 777

Drug cost

$870,887

Median for Internal Medicine: $73,373

Branded share of claims

19.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 130 $152,278
Mounjaro Tirzepatide Brand 88 $107,736
Jardiance Empagliflozin Brand 81 $97,363
Ozempic Semaglutide Brand 68 $80,355
Farxiga Dapagliflozin Propanediol Brand 27 $39,413
Januvia Sitagliptin Phosphate Brand 26 $27,972
Entresto Sacubitril/Valsartan Brand 16 $23,611
Trulicity Dulaglutide Brand 11 $23,100
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 24 $22,537
Xarelto Rivaroxaban Brand 15 $21,233

The 10 drugs with the highest cost, of 158 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$178,977

Of which drugs: $20,084

Medicare patients

632

Average age 75

Services billed

2,907

314 women, 318 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 35%
Chronic kidney disease 33%
Diabetes 30%
Depression 28%
Atrial fibrillation 20%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 39 39 $11,281
Vaccine for influenza for injection into muscle 90662 Office 102 105 $8,502
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 17 30 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $116
$116 24 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $109
$109 — —
MOUNJARO
  • Lilly USA, LLC $107
$107 88 —
GEMTESA
  • Sumitomo Pharma America, Inc. $83
$83 12 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $36
  • Lilly USA, LLC $21
$57 81 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

348 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record